Floatz logo

FX909

Open Label

Flare Therapeutics Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Open Label cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Flare Therapeutics Inc.
Phase 1CC

Same molecule, other indications

FX909 is also rated in:

urothelial carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
Oral Drug AdministrationDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →